近年来,我国生物医药行业发展支持政策陆续出台、不断优化,关键技术取得一定突破、国际化战略逐步落地,行业在转型中稳步发展,创新药企也展现出强劲的创新活力与市场竞争力。 随着2024年年报陆续披露,在21世纪经济报道选取的十家创新药企中,从营收维度看,有七家实现同比增长。其中,得益于与BMS(百时美施贵宝)就创新药BL-B01D1 达成BD(商务拓展)交易确认的收入,百利天恒营收增幅高达...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.